Acura Pharmaceuticals (ACUR) Earning Somewhat Favorable News Coverage, Analysis Finds
News coverage about Acura Pharmaceuticals (NASDAQ:ACUR) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Acura Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 45.8893575828893 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Acura Pharmaceuticals, Inc. (ACUR) Issues Quarterly Earnings Results (americanbankingnews.com)
- ACURA PHARMACEUTICALS : Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) (4-traders.com)
- Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Gradient Investments LLC Acquires New Stake in Progenics Pharmaceuticals Inc. (PGNX) (wisdomsave.com)
Acura Pharmaceuticals (ACUR) traded down 6.709% during midday trading on Tuesday, hitting $0.438. The company’s stock had a trading volume of 12,350 shares. The company’s 50-day moving average is $0.51 and its 200 day moving average is $0.57. The company’s market cap is $5.20 million. Acura Pharmaceuticals has a one year low of $0.40 and a one year high of $1.87.
Acura Pharmaceuticals (NASDAQ:ACUR) last posted its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.07. Acura Pharmaceuticals had a return on equity of 112.19% and a net margin of 14.91%. The company had revenue of $0.09 million for the quarter. On average, analysts predict that Acura Pharmaceuticals will post ($0.46) EPS for the current year.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.